Biopharmaceutical - Drug Discovery and Development (Peptide Therapeutics)
Strategic Profile
The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates. Revenue generation is predominantly through strategic collaborations with leading global pharmaceutical companies, licensing access to its PDPS technology and collaborating on drug discovery projects, securing upfront payments, research funding, milestone payments, and potential royalties.
Cyborg Score Rationale
The company achieved 62.6% revenue growth in 2024 and 394.6% net income growth. PeptiDream recently advanced an oral dual IL-17 program into its clinical portfolio and hit a preclinical siRNA delivery milestone with Alnylam. However, year-to-date share price return has been negative 33.87 percent, contributing to cautious investor sentiment.
Top Insights
2024 revenue reached $323.0M with 62.6% YoY growth.
The company has 750+ employees spanning discovery, development, manufacturing, regulatory, and sales across the PeptiDream Group including PDRadiopharma subsidiary.
Collaborations with Eli Lilly, Bristol-Myers Squibb, AstraZeneca, and other major pharma companies provide revenue visibility and validation.
AI-driven drug discovery advancements and peptide engineering improvements enable faster high-value candidate identification and support higher-margin licensing deals.
Named Competitors
Constrained Peptide Drug Discovery — Competitor in peptide-based drug discovery
Macrocyclic Peptide Therapeutics — Various competitors in peptide drug space
Recent Developments
(December 2025) Advanced oral dual IL-17 program into clinical portfolio and achieved siRNA delivery milestone with Alnylam
(May 2024) Expanded peptide discovery collaboration with Novartis in $2.7B deal
(2024) Posted $323M in revenue with 62.6% growth and swing to profitability with 394.6% net income growth
Open the full interactive PeptiDream Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.